Anthem Biosciences: Fueling Global Pharma with Massive Expansion

Anthem Biosciences, a leading contract research, development, and manufacturing organization (CRDMO), is significantly expanding its infrastructure to meet rising global demand for fermentation-based APIs and complex custom synthesis solutions.

The company recently commissioned its third manufacturing facility in Karnataka, focused on peptides and fermentation, with an investment of ₹600 crore. Construction is also underway on a fourth, large-scale unit spanning 30 acres—larger than its first three units combined—which is expected to be operational within two years. Anthem’s total gross block now exceeds ₹1,300 crore, with an additional ₹300 crore in capital work-in-progress.

With more than 80% of its revenue derived from exports to the US, Europe, and China, Anthem specializes in high-margin segments such as probiotics, enzymes, peptides, and vitamins. It works directly with global pharmaceutical innovators, contributing to New Drug Applications (NDAs) by supplying advanced intermediates and APIs.

This phase of strategic growth aligns with the company’s upcoming ₹3,395-crore initial public offering (IPO), set to open from July 14 to 16.

News by Rahul Yelligetti.